XXXX -based induction for transplant ineligible @entity2783 and feasibility of later transplantation.

@entity1 @entity2783 @entity786 @entity619 @entity1749
Recent studies support the use of @entity1749 -based therapies in light chain @entity2783 ( @entity2783 ). We performed a retrospective analysis of the safety, efficacy and long-term survival (median follow-up 3 years) after @entity1749 -based treatment in 28 consecutive @entity1 with de novo @entity2783 deemed ineligible at initial presentation. The first 14 @entity1 received @entity1749 and @entity619 (VD), and the second 14 @entity1 received @entity786 , @entity1749 and @entity619 (CVD; CyBorD). Both regimens were well tolerated with no treatment-related mortality. The overall hematological response (HR) rate was 93% in both the groups. Median time to response was shorter in the CVD group (39 days vs 96 days in the VD group; P=0.002). Hematological and organ responses induced with @entity1749 -based therapy enabled 8 (33%) of initially transplant ineligible @entity1 to undergo autologous hematopoietic stem cell transplantation (AHCT), including 4 @entity1 with cardiac stage III or IV. Seven of the eight @entity1 (88%) who underwent subsequent AHCT achieved sustained HR at a median of 33 months posttransplant. These data suggest that @entity1749 -based induction followed by AHCT is a viable therapeutic strategy for transplant-ineligible @entity2783 . Larger, multicenter prospective trials are necessary to confirm our findings.
